Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in ...
Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ovarian (40%; N=10) and HR+ HER2- breast (43%; N=7) cancer, in addition to a favorable safety profile Phase 2 study in platinum- …